Breath4Research’s Post

I recently read an important article that provides key insights into the potential disadvantages of using a placebo in randomized trials for the maintenance of remission in inflammatory bowel disease (IBD). The study systematically analyzed data from trials involving biologics and small molecules and highlighted critical risks. 🔑 Here are the key takeaways: 1️⃣ There were no significant differences between active drugs and placebo for overall treatment-emergent adverse events, serious infections, or venous thromboembolic events. 2️⃣ Active drugs showed higher risks of infections (RR: 1.14) and drug-related adverse events (RR: 1.24). 💊 Benefits of Active Drugs: Active treatments were associated with lower risks of worsening IBD activity (RR: 0.58), serious adverse events (RR: 0.85), and withdrawals due to adverse events (RR: 0.71). ✳️ Placebo Risks: Placebo use was linked with clinically meaningful harms, especially an increased risk of worsening IBD activity, highlighting the need for careful patient counseling. 🛣️ My view: ↗️ This article highlights the importance of balancing patient safety with rigorous testing in clinical trials. ↗️ It also encourages exploring alternative trial designs to minimize risks while effectively evaluating new therapies for IBD. #IBD #ClinicalTrials #PatientSafety #Gastroenterology #MetaAnalysis #PharmaResearch #Biologics #EvidenceBasedMedicine

Many intrathecally delivered neurotherapeutics continue to fail. This is likely due to the inability of these drugs to penetrate deep into the brain parenchyma. Efficacy in these studies is measured by quantifying the target protein level in cerebrospinal fluid (CSF), showing reductions in comparison to controls. However, reductions in CSF levels of the protein does not correlate with reduced protein expression levels in brain tissue. While CSF marker levels may change, the drugs only affect cells neighboring the ventricles, with most of the drug getting washed out. Our portfolio of advancements in intravenous (IV) delivered neurotherapeutics is making homogeneous reduction of toxic protein levels throughout the central nervous system and peripheral tissues possible. I will be in San Diego, Texas and Boston in June for strategic discussions around our programs that can improve outcomes for patients with neurological diseases. Please reach out to learn more. https://lnkd.in/gy56y535

Insilico Medicine announced positive topline results from the Phase 2a trial of ISM001-055, the novel drug candidate developed in-house using generative AI to target TNIK (Traf2- and NCK- interacting kinase) for the treatment of idiopathic pulmonary fibrosis (IPF). The results demonstrate that ISM001-055 is safe, well-tolerated, exhibits a favorable pharmacokinetics (PK) profile, and has encouraging clinical efficacy as measured by improvement in forced vital capacity (FVC) at 12 weeks. "I am very impressed by the positive results observed in IPF patients treated with ISM001-055, particularly the encouraging improvement in FVC. It not only reflects ISM001-055's potential to slow disease progression but also suggests its capability to stop or even reverse it," said Zuojun Xu, M.D., Professor of Peking Union Medical College and the principal investigator in the Phase 2a trial of ISM001-055 in IPF patients. #IPFTreatment #ClinicalTrials #PharmaInnovation #BiotechBreakthrough #PulmonaryFibrosis #AIinDrugDiscovery #DrugDevelopment #Pharmacokinetics #TNIKInhibitor #MedicalResearch #HealthTech #LifeSciences #PositiveResults #TransformingHealthcare #QimingPortfolio #QimingHealthcare Read More: https://lnkd.in/gZzC4a-D

📰 Personalized Treatment for Type 2 Diabetes: A Revolution in Progress! A recent article in Cell Discovery presents a major breakthrough in the treatment of Type 2 Diabetes (T2D). Researchers successfully implanted pancreatic islet tissues derived from endoderm stem cells (EnSCs) in a patient, significantly improving their glycemic control without the need for exogenous insulin. This study is particularly fascinating for several reasons: 🔬 Cutting-edge technology: The islet tissues were generated from human pluripotent stem cells, providing a new source for tissue replacement therapies. 💉 Promising results: The treated patient showed significant improvements in glycemic control, with a marked reduction in glucose fluctuations and the elimination of both hyperglycemic and hypoglycemic episodes. 🔄 Clinical application: This therapy could revolutionize the treatment of diabetic patients by offering an alternative to daily insulin injections. Key points of the study: Durability and safety: No episodes of tumor formation were observed during the 116-week follow-up period. Rapid improvement: Notable improvements were observed as early as the first few weeks post-transplantation, including a reduction in glycemic variability. Insulin independence: The patient was able to completely stop exogenous insulin after just 11 weeks. #Diabetes #ClinicalResearch #Biotechnology #HealthInnovation #CellTherapy #Pharmaceuticals https://lnkd.in/eF282Skw

💎💎Whatsapp!! 💎💎 regenerates lung tissue & new drug prototype. How a New #Drug Prototype #Regenerates #Lung Tissue A new study from Scripps Research and Calibr-Skaggs scientists provides #pharmacological proof of concept for an upcoming phase 1 #clinical_trial. #Pulmonary_diseases are a leading cause of #morbidity and #mortality worldwide. For many progressive lung diseases like #idiopathic pulmonary #fibrosis (IPF), a key issue is a low supply of new #stem #cells to repair and reverse the damage. These cells are responsible for #regenerating and increasing the growth of healthy #tissue—without them, lung function decreases and a range of severe #illnesses can take hold. ➡ 💎 You can find more pieces of work by clicking here. https://lnkd.in/eSG67K5G #Drug #Prototype #Regenerates #Lung #Tissue #clinical_trial #pharmacological #Pulmonary_diseases #morbidity #mortality #idiopathic #fibrosis #stem #cells #regenerating #tissue—without #illnesses

🌟 A Historic Milestone for Regenerative Medicine: FDA Approves the First MSC Therapy! The recent FDA approval of the first mesenchymal stromal cell (MSC) therapy for treating steroid-refractory acute graft-versus-host disease (SR-aGVHD) is a game-changer in regenerative medicine and cell-based therapies. This milestone validates decades of research and development, bringing hope to patients with limited treatment options. Why This Matters: 🔬 Scientific Validation: This approval underscores MSCs’ potential in modulating the immune response and fostering tissue repair. 💉 Clinical Impact: Patients suffering from life-threatening SR-aGVHD, often following bone marrow transplants, now have an FDA-approved treatment backed by rigorous clinical data. 🌍 Global Influence: The decision could pave the way for broader regulatory approvals, fostering more investment and innovation in MSC-based therapies worldwide. Looking Ahead: This landmark approval signals that the era of MSC-based therapies has arrived. As a cell therapy professional, I’m excited about the opportunities this opens for advancing novel treatments for other severe conditions, including autoimmune diseases and tissue repair applications. Let’s celebrate this achievement and continue working toward a future where regenerative medicine transforms lives! Read more here: https://lnkd.in/g4cSQBDv #CellTherapy #MSCTherapy #FDAApproval #RegenerativeMedicine #BiotechInnovation #HealthcareBreakthrough

🔬 Check out last months top science briefs! 🌬️ Unveiling the potential of pulmonary surfactant-based nanocarriers for protein inhalation therapy https://bit.ly/3PPH4Do 🩺 Comparative Preclinical Pharmacokinetics and Disposition of Favipiravir Following Pulmonary and Oral Administration as Potential Adjunct Therapy Against Airborne RNA Viruses https://bit.ly/4h97gF4 🏥 Characterization of pediatric extrathoracic aerosol deposition with air-jet dry powder inhalers https://bit.ly/3ElOLi4 👃🏽 Dry powder inhaler deposition in the larynx and the risk of steroid inhaler laryngitis: A computational fluid dynamics study https://bit.ly/4gewpNw ♻️ The environmental burden of inhalation https://bit.ly/4h7HktA 🔬 Posaconazole nanocrystals dry powder inhalers for the local treatment of invasive pulmonary aspergillosis https://bit.ly/4h9JI2Q 🧠 Advancement in the Nose-to-Brain Drug delivery of FDA-approved drugs for the better management of Depression and Psychiatric disorders https://bit.ly/4gaI4wK 🦠 Impact of protein aggregation on the immunogenicity of a human monoclonal antibody following pulmonary administration in mice https://lnkd.in/eHGZjETC 3️⃣ Triple inhaled therapy in asthma: Beliefs, behaviours and doubts https://bit.ly/4gewnVU 🫁 Interaction between fluticasone furoate and umeclidinium in passively sensitized isolated human airways https://bit.ly/4g66G9S 🥼 Lipid nanoparticles for pulmonary fibrosis: A comprehensive review https://bit.ly/3PNaYIw 🏅 Ensifentrine approval: A milestone in the treatment of COPD https://bit.ly/4h7XUJE

𝗥𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝗶𝘇𝗶𝗻𝗴 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲: 𝗣𝗹𝗮𝘀𝗺𝗮𝗽𝗵𝗲𝗿𝗲𝘀𝗶𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 𝘁𝗼 𝗛𝗶𝘁 $𝟮.𝟱𝟱 𝗕𝗶𝗹𝗹𝗶𝗼𝗻 𝗯𝘆 𝟮𝟬𝟯𝟬!   *𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗳𝗼𝗿 𝗦𝗮𝗺𝗽𝗹𝗲 𝗣𝗗𝗙: https://lnkd.in/g4APWfND   Plasmapheresis is a procedure involving the removal, treatment, and reinfusion or exchange of plasma from the body’s circulatory system. This process can be used therapeutically to treat conditions like autoimmune diseases, blood disorders, and neurological disorders, or for sourcing plasma to produce blood-derived products. The procedure involves specialized equipment that separates plasma from blood cells. The global demand for plasmapheresis systems is rising due to an increasing need for plasma exchange and source plasma for therapeutic use. Market growth is largely driven by the rising prevalence of autoimmune diseases, the growing demand for source plasma among biopharmaceutical companies, and supportive reimbursement policies. Additionally, increasing demand for plasmapheresis in emerging markets offers promising opportunities for expansion. However, the high cost of devices and procedures, as well as risks associated with the procedure, pose challenges to market growth. Limited awareness of plasmapheresis and restricted access in certain regions also represent significant barriers for this market. 𝗣𝗹𝗮𝘀𝗺𝗮𝗽𝗵𝗲𝗿𝗲𝘀𝗶𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 𝗦𝗲𝗴𝗺𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻𝘀: *𝗕𝘆 𝗣𝗿𝗼𝗱𝘂𝗰𝘁: Instruments, Disposables *𝗕𝘆 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆: Centrifugation, Membrane Filtration *𝗕𝘆 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀: Source Plasma Collection, Therapeutic Plasmapheresis (Immunology, Neurology, Hematology, Critical Care, Hematology-oncology, Rheumatology & Orthopedics, Other Therapeutic Applications)   *𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬: Terumo Medical Corporation Baxter International Inc. B. Braun Group KANEKA CORPORATION Haemonetics   *𝐁𝐲 𝐑𝐞𝐠𝐢𝐨𝐧: North America, Europe, Asia-Pacific (APAC), Latin America and Middle East & Africa   𝗥𝗲𝗹𝗮𝘁𝗲𝗱 𝗥𝗲𝗽𝗼𝗿𝘁𝘀: Medical Imaging Market: https://lnkd.in/gPgneuuY   Defibrillator Market: https://lnkd.in/g87WiRKQ Dental Prosthetics Market: https://lnkd.in/g5Yf8Nwq #Plasmapheresis #PlasmaExchange #AutoimmuneDiseases #BloodDisorders #HealthcareInnovation #TherapeuticPlasmapheresis #PlasmaTherapy #Biopharmaceuticals #MedicalDevices #EmergingMarkets

Working with in vitro cardiotoxicity models? Looking for functional atrial cardiomyocytes for arrhythmia models? We can help! We've pulled together everything you need to know about our axoCells™ Atrial Cardiomyocytes including: ·      Key features and applications including cardiac safety pharmacology and modeling AF and other arrhythmias ·      Data behind the phenotypic characterization and functional relevance of our atrial cardiomyocytes, including chamber-specific pharmacological responses ·      Essential ordering information and user protocols Take a look at the graphic to see the atrial cardiomyocyte chapter of our axoCells Catalog, and click here to download the full thing: https://lnkd.in/epUnnZWt If you'd like to learn more about our work with iPSC-derived ventricular and atrial cardiomyocytes, click here to explore our 2024 Cardiac Guide: https://lnkd.in/eWWWV_-s #iPSCs #AtrialCardiomyocytes #AtrialFibrillation #cardiotoxicity #StemCells